Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 181

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 181
---
 resolution including, if required by the applicable Stock Exchange, disinterested shareholder approval, to make amendments to the Plan not contemplated above, including, but not limited to:

(a)any change to the number of common shares issuable from treasury under the Plan, including an increase to the fixed maximum percentage or number of common shares or a change from a fixed maximum percentage of common shares to a fixed maximum number of common shares or vice versa;

(b)any amendment which reduces the exercise price of any Award, provided, however, that, for greater certainty, disinterested shareholder approval will be required for any amendment which reduces the exercise price of any Option if the Participant is an insider of the Company at the time of the proposed amendment;

(c)any amendment which extends the expiry date of an Award, or the restriction period of any RSU beyond the original expiry date or restriction period, except in the event of an extension due to a blackout period;

(d)any amendment which cancels any Award and replaces such Award with an Award which has a lower exercise price or other entitlement;

(e)any amendment which would permit Awards to be transferred or assigned by any Participant; and

(f)any amendments to the amendment provisions of the Plan.

Notwithstanding the foregoing: any amendment to the Plan shall be subject to the receipt of all required regulatory approvals including, without limitation, the approval of the Stock Exchange.

The following table sets forth the number of common shares to be issued, including upon exercise of outstanding convertible securities, pursuant to the Company's equity compensation plans, the weighted-average exercise price of such outstanding convertible securities and the number of common shares remaining available for future issuance under equity compensation plans as at December 31, 2024.

| Plan Category                                              |         Number of common 
 shares to be issued upon 
  exercise of outstanding 
    Options, warrants and 
                   rights | Weighted-average     
 exercise price of    
 outstanding Options, 
 warrants and rights  |      Number of common 
      shares remaining 
  available for future 
 issuance under equity 
    compensation plans |
| Equity compensation plans approved by security holders     |                1,185,000 | C$2.06               |               801,556 |
| Equity compensation plans not approved by security holders |                        - | -                    |                     - |
| Total                                                      |                1,185,000 | C$2.06               |               801,556 |

<div align='center'>128

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</div